“RB-reactivator screening” as a novel cell-based assay for discoveries of molecular targeting agents including the first-in-class MEK inhibitor trametinib (trade name: Mekinist)-Reference-Cited by-同舟云学术

“RB-reactivator screening” as a novel cell-based assay for discoveries of molecular targeting agents including the first-in-class MEK inhibitor trametinib (trade name: Mekinist)

Published:2022-08 Issue: Volume:236 Page:108234
ISSN:0163-7258
Container-title:Pharmacology & Therapeutics
language:en
Short-container-title:Pharmacology & Therapeutics

Author:

Sakai Toshiyuki

Publisher

Elsevier BV

Subject

Pharmacology (medical),Pharmacology

Reference75 articles.

1. Promoter activation and following induction of the p21/WAF1 gene by flavone is involved in G1-phase arrest in A549 lung adenocarcinoma cells;Bai;FEBS Letters,1998

2. C-Raf, but not B-Raf, is essential for development of K-Ras oncogene-driven non-small cell lung carcinoma;Blasco;Cancer Cell,2011

3. Improved survival with vemurafenib in melanoma with BRAF V600E mutation;Chapman;New England Journal of Medicine,2011

4. The E2F transcription factor is a cellular target for the RB protein;Chellappan;Cell,1991

5. Fucoxanthin induces cell cycle arrest at G0/G1 phase in human colon carcinoma cells through up-regulation of p21WAF1/Cip1;Das;Biochimica et Biophysica Acta,2005

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Suppression of Interferon Response and Antiviral Strategies of Bunyaviruses;Tropical Medicine and Infectious Disease;2024-09-07

2. Epithelial-mesenchymal transition status is a remarkable biomarker for the combination treatment with avutometinib and defactinib in KRAS-mutated non-small cell lung cancer;British Journal of Cancer;2024-05-31

3. Clinical research progress on BRAF V600E-mutant advanced colorectal cancer;Journal of Cancer Research and Clinical Oncology;2023-08-28

4. Identification of c-Met as a novel target of γ-glutamylcyclotransferase;Scientific Reports;2023-07-24

5. Trametinib for patients with recurrent low-grade serous ovarian cancer: A cost-effectiveness analysis;Gynecologic Oncology;2023-01